SCHEMBL3769717

SCHEMBL3769717

CN(C)Cc1ccccc1Nc1nccc(-c2c(Cl)nc3sccn23)n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 7/20 0.46
LCK P06239 7/20 0.46
IGF1R P08069 6/20 0.46
CSF1R P07333 5/20 0.46
PTK2 Q05397 2/20 0.46
RET P07949 5/20 0.46
MAP4K4 O95819 5/20 0.46
FLT1 P17948 4/20 0.46
MAP4K2 Q12851 4/20 0.46
STK3 Q13188 4/20 0.46
MAP4K5 Q9Y4K4 4/20 0.46
TAOK1 Q7L7X3 3/20 0.46
PRKD3 O94806 2/20 0.46
FYN P06241 2/20 0.46
MET P08581 2/20 0.46
ROS1 P08922 2/20 0.46
AURKB Q96GD4 2/20 0.46
ABL1 P00519 2/20 0.46
PAK4 O96013 1/20 0.46
GSK3B P49841 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3764194 0.83 KDR (0.45) KDRLCKIGF1RCSF1RPTK2
SCHEMBL3764192 0.83 IGF1R (0.49) KDRLCKIGF1RCSF1RPTK2
SCHEMBL3758950 0.82 MAPK8 (0.50) KDRLCKIGF1RCSF1RPTK2
SCHEMBL3762763 0.80 EGFR (0.59) KDRLCKIGF1RCSF1RPTK2
SCHEMBL12996178 0.77 KDR (0.46) KDRLCKIGF1RCSF1RPTK2
SCHEMBL3756694 0.76 IGF1R (0.66) KDRLCKIGF1RCSF1RPTK2
SCHEMBL3723424 0.76 IGF1R (0.52) KDRLCKIGF1RCSF1RPTK2
SCHEMBL3759707 0.75 MKNK2 (0.46) KDRLCKIGF1RCSF1RPTK2
SCHEMBL3769704 0.72 PLK1 (0.52) IGF1RROS1EGFR
SCHEMBL3767841 0.71 KDR (0.45) KDRLCKMAP4K4FLT1PRKD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2435435-B1 PYRIMIDINE INHIBITORS OF KINASE ACTIVITY ABBVIE INC (US) 2014-01-29 EP disclosed
US-8536180-B2 Pyrimidine inhibitors of kinase activity ABBVIE INC. (US) 2013-09-17 US disclosed
WO-2010138575-A1 PYRIMIDINE INHIBITORS OF KINASE ACTIVITY ABBOTT LABORATORIES (US) 2010-12-02 WO disclosed
US-20100305118-A1 PYRIMIDINE INHIBITORS OF KINASE ACTIVITY ABBOTT LABORATORIES (US) 2010-12-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305118-A1 PYRIMIDINE INHIBITORS OF KINASE ACTIVITY IGF1R, TK1, CDK2 KDR 351/4885LCK 715/4885IGF1R 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.